- Home
- TKLF vs PHIO Comparison
TKLF vs PHIO Comparison
Compare TKLF & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- PHIO
- Stock Information
- Founded
- TKLF 2006
- PHIO 2011
- Country
- TKLF Japan
- PHIO United States
- Employees
- TKLF N/A
- PHIO N/A
- Industry
- TKLF Other Specialty Stores
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- PHIO Health Care
- Exchange
- TKLF Nasdaq
- PHIO Nasdaq
- Market Cap
- TKLF 15.6M
- PHIO 12.8M
- IPO Year
- TKLF 2022
- PHIO N/A
- Fundamental
- Price
- TKLF $2.72
- PHIO $1.18
- Analyst Decision
- TKLF
- PHIO Strong Buy
- Analyst Count
- TKLF 0
- PHIO 3
- Target Price
- TKLF N/A
- PHIO $10.67
- AVG Volume (30 Days)
- TKLF 16.3K
- PHIO 8.8M
- Earning Date
- TKLF 12-17-2025
- PHIO 11-13-2025
- Dividend Yield
- TKLF N/A
- PHIO N/A
- EPS Growth
- TKLF N/A
- PHIO N/A
- EPS
- TKLF 1.57
- PHIO N/A
- Revenue
- TKLF $210,119,238.00
- PHIO N/A
- Revenue This Year
- TKLF N/A
- PHIO N/A
- Revenue Next Year
- TKLF N/A
- PHIO N/A
- P/E Ratio
- TKLF $1.74
- PHIO N/A
- Revenue Growth
- TKLF 7.38
- PHIO N/A
- 52 Week Low
- TKLF $2.59
- PHIO $0.97
- 52 Week High
- TKLF $4.32
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- TKLF 31.96
- PHIO 24.02
- Support Level
- TKLF $2.84
- PHIO $1.08
- Resistance Level
- TKLF $2.92
- PHIO $1.32
- Average True Range (ATR)
- TKLF 0.23
- PHIO 0.14
- MACD
- TKLF -0.03
- PHIO -0.03
- Stochastic Oscillator
- TKLF 29.41
- PHIO 16.05
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.